CHMP backs Joenja for APDS, putting EU approval within reach
Pharming has picked up an important European regulatory win for Joenja, its oral leniolisib therapy for activated phosphoinositide 3-kinase delta syndrome, or APDS. The EMA’s CHMP adopted a positive opinion recommending marketing authorization for adults and pediatric patients age 12 and older, positioning the drug for a final European Commission decision in roughly two months. If approved, Joenja would be the first authorized treatment for APDS in the EU. (stocktitan.net)
The opinion follows a long review process. In May 2024, Pharming said CHMP had affirmed the drug’s positive clinical benefit and safety profile, in line with an ad hoc expert group assessment, but asked for additional chemistry, manufacturing, and controls information related to regulatory starting materials. The committee required that work to be completed before approval and granted the company until January 2026 to respond, delaying the EU timeline even as the clinical case for the drug appeared settled. (pharming.com)
Joenja’s clinical foundation is already established in the U.S. FDA approved the drug on March 24, 2023, as the first treatment for APDS in adults and pediatric patients 12 and older. That approval was based on a 12-week randomized, placebo-controlled study of 31 patients with genetically confirmed APDS, with co-primary endpoints focused on lymph node reduction and normalization of naïve B-cell percentages. Pharming said the EU filing also included long-term extension data from 37 patients treated with leniolisib for a median of three years. (fda.gov)
The company is also widening Joenja’s geographic footprint beyond the U.S. and prospective EU launch. Pharming said Japan approved Joenja on March 24, 2026, for adults and children age 4 and older, marking the product’s first approval covering the 4-to-11 age group. In the U.K., NICE issued positive final guidance in April 2025 recommending reimbursement and NHS use in England and Wales for eligible patients 12 and older. (pharming.com)
On expert reaction, Pharming highlighted comments from Virgil Dalm, MD, PhD, of Erasmus University Medical Center, a principal investigator in the clinical program, who said the data showed consistent and meaningful improvements across markers of immune dysregulation and immune deficiency, alongside a favorable safety profile. As with many company-issued quotes, that perspective is supportive rather than independent, but it reinforces the core regulatory message: European reviewers appear to have moved past earlier procedural hurdles and accepted the benefit-risk case. (stocktitan.net)
Why it matters: While this is a human rare-disease story, it’s relevant to veterinary professionals who follow translational medicine, specialty pharmacy, and the regulatory playbook for targeted therapies. APDS is a genetically defined immune disorder tied to variants in PIK3CD or PIK3R1, and Joenja is designed to address the overactive PI3K-delta pathway behind the disease. The case underscores two broader themes: first, rare-disease drugs can still face lengthy approval timelines even with favorable efficacy data, and second, manufacturing and quality documentation can be the deciding factor between momentum and delay. (fda.gov)
It also highlights the commercial reality of orphan drugs. A positive CHMP opinion is not the endpoint; country-by-country reimbursement, treatment-center uptake, diagnostic capacity, and clinician awareness will determine how many patients actually gain access. That may be especially important in APDS, which Pharming says is often misdiagnosed and associated with a median diagnostic delay of seven years, raising the stakes for earlier recognition and referral. (stocktitan.net)
What to watch: The immediate next step is the European Commission decision, expected in Q2 2026, followed by pricing and reimbursement negotiations across Europe; separately, Pharming is still working through pediatric expansion questions in the U.S. after receiving a Complete Response Letter in February 2026 for children ages 4 to 11. (stocktitan.net)